Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126980592 | 12698059 | 2 | F | 2007 | 20160815 | 20160830 | 20160929 | PER | US-JNJFOC-20160617295 | JANSSEN | 0.00 | C | M | Y | 113.40000 | KG | 20160929 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126980592 | 12698059 | 1 | SS | RISPERDAL | RISPERIDONE | 1 | Oral | U | 0 | .5 | MG | UNSPECIFIED | |||||||
| 126980592 | 12698059 | 2 | SS | RISPERDAL | RISPERIDONE | 1 | Oral | U | 0 | UNSPECIFIED | |||||||||
| 126980592 | 12698059 | 3 | SS | RISPERDAL | RISPERIDONE | 1 | Oral | U | 0 | UNSPECIFIED | |||||||||
| 126980592 | 12698059 | 4 | PS | RISPERDAL | RISPERIDONE | 1 | Oral | U | 20272 | .5 | MG | UNSPECIFIED | |||||||
| 126980592 | 12698059 | 5 | SS | INVEGA | PALIPERIDONE | 1 | Oral | U | U | 0 | 3 | MG | OROS (ORAL OSMOTIC) THERAPEUTIC SYSTEM TABLET | ||||||
| 126980592 | 12698059 | 6 | SS | INVEGA | PALIPERIDONE | 1 | Oral | U | U | 21999 | 3 | MG | OROS (ORAL OSMOTIC) THERAPEUTIC SYSTEM TABLET | ||||||
| 126980592 | 12698059 | 7 | SS | RISPERIDONE. | RISPERIDONE | 1 | Oral | U | U | 0 | .25 | MG | UNSPECIFIED | ||||||
| 126980592 | 12698059 | 8 | SS | RISPERIDONE. | RISPERIDONE | 1 | Oral | U | U | 0 | .5 | MG | UNSPECIFIED | ||||||
| 126980592 | 12698059 | 9 | SS | RISPERIDONE. | RISPERIDONE | 1 | Oral | U | U | 0 | .25 | MG | UNSPECIFIED | ||||||
| 126980592 | 12698059 | 10 | SS | RISPERIDONE. | RISPERIDONE | 1 | Oral | U | U | 20272 | .5 | MG | UNSPECIFIED | ||||||
| 126980592 | 12698059 | 11 | SS | RISPERIDONE. | RISPERIDONE | 1 | Oral | U | 0 | TABLET |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126980592 | 12698059 | 1 | Bipolar disorder |
| 126980592 | 12698059 | 2 | Bipolar disorder |
| 126980592 | 12698059 | 3 | Attention deficit/hyperactivity disorder |
| 126980592 | 12698059 | 4 | Attention deficit/hyperactivity disorder |
| 126980592 | 12698059 | 5 | Bipolar disorder |
| 126980592 | 12698059 | 6 | Attention deficit/hyperactivity disorder |
| 126980592 | 12698059 | 7 | Bipolar disorder |
| 126980592 | 12698059 | 8 | Bipolar disorder |
| 126980592 | 12698059 | 9 | Attention deficit/hyperactivity disorder |
| 126980592 | 12698059 | 10 | Attention deficit/hyperactivity disorder |
| 126980592 | 12698059 | 11 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126980592 | 12698059 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126980592 | 12698059 | Depression | |
| 126980592 | 12698059 | Emotional disorder | |
| 126980592 | 12698059 | Gynaecomastia | |
| 126980592 | 12698059 | Weight increased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126980592 | 12698059 | 1 | 20060907 | 20070810 | 0 | |
| 126980592 | 12698059 | 2 | 20131030 | 0 | ||
| 126980592 | 12698059 | 3 | 20131030 | 0 | ||
| 126980592 | 12698059 | 4 | 20060907 | 20070810 | 0 | |
| 126980592 | 12698059 | 5 | 20070718 | 20070816 | 0 | |
| 126980592 | 12698059 | 6 | 20070718 | 20070816 | 0 | |
| 126980592 | 12698059 | 7 | 20130508 | 20130822 | 0 | |
| 126980592 | 12698059 | 8 | 20130822 | 20131023 | 0 | |
| 126980592 | 12698059 | 9 | 20130508 | 20130822 | 0 | |
| 126980592 | 12698059 | 10 | 20130822 | 20131023 | 0 |